

FW

FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

SUITE 401L - 1801 K STREET, NW
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LA SALLE STREET, CHICAGO, ILLINOIS 60603-3406

TELEPHONE (312) 577-7000

CALIFORNIA OFFICES

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121

TELEPHONE (619) 552-1311

WARNER CENTER TOWERS, SUITE 780, 21800 OXNARD ST., WOODLAND HILLS, CA 91367

TELEPHONE (818) 715-7025


COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302

TELEPHONE (303) 402-6966

April 1, 2005

MORGAN L. FITCH, JR.
FRANCIS A. EVEN*
JULIUS TABIN*
JOHN F. FLANNERY
ROBERT B. JONES
JAMES J. SCHUMANN
JAMES J. HAMILL
TIMOTHY E. LEVSTIK
JOSEPH E. SHIPLEY
KENNETH H. SAMPLES
PHILIP T. PETTI
JOSEPH T. NABOR
STEVEN C. SCHROER
RICHARD A. KABA*
KARL R. FINK
MARK W. HETZLER
TIMOTHY P. MALONEY
JAMES P. KRUEGER
STEPHEN S. FAVAKEH
RICHARD E. WAWRZYNIAK
STEVEN G. PARMELEE
THOMAS F. LEBENS
BRUCE R. MANSFIELD
KENDREW H. COLTON*
G. PAUL EDGELL*
MICHAEL A. SANZO*
SCOTT J. MENGHINI
NORMAN N. KUNITZ*
RUDY KRATZ
RAMON R. HOCH*
JOHN D. BAUERSFELD*
GARY D. MANN



EDWARD E. CLAIR
JON A. BIRMINGHAM
JOHN E. LYHUS
STEVEN M. FREELAND
DONNA E. BECKER
BRIAN S. CLISE
MARTIN R. BADER
MARK A. BORSOS
TIMOTHY R. BAUMANN
JEFFREY A. CHELSTROM
NICHOLAS T. PETERS
KENNETH E. PLOCHINSKI
GRACE LAW O'BRIEN
CHRISTINE A. ABUEL
TARA M. REEDY

PATENT AGENTS

ERIC J. WHITESELL
LILIA I. SAFONOV
NADA J. ARDELEANU
JULIE A. HOPPER

OF COUNSEL

GEORGE W. SPELLMIRE, JR.
LISA M. SOMMER
GEORGE H. SPENCER, P.C.*

TECHNICAL ADVISOR

JOHN M. BRONK, PH.D.

*ADMITTED TO D.C. BAR
D.C. PRACTICE OF ALL OTHERS
LIMITED TO FEDERAL COURTS
AND AGENCIES

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, MS Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Re: Second Supplemental Information Disclosure Statement
Appl. No.: 10/612,338
Filed: July 3, 2003
Title: **Compositions and Methods Involving the
Combination of a Thromboxane A2 Receptor
Antagonist and an Inhibitor of Cyclooxygenase-2**
Inventor(s): Brunner, Hans R.
Atty. Dkt.: 7571/80526

Sir:

The following documents are being forwarded for appropriate action by the U.S. Patent and Trademark Office:

1. Second Supplemental Information Disclosure Statement;
2. PTO Form-1449, List of References Cited by Applicant;
3. References AL1-AO1; and
4. Return postcard.


Commissioner of Patents
April 1, 2005
Page 2

Applicant does not believe that any fee is due for the filing of this Information Disclosure Statement. However, the Director is hereby authorized to charge any fee deficiency with respect to this filing and any other fee required in connection with the present case, or credit any overpayment, to our Deposit Account No. 06-1135 under Order No. 7571/80526.

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

A handwritten signature in black ink that reads "Michael A. Sanzo". The signature is written in a cursive, flowing style.

Michael A. Sanzo
Attorney for Applicant
Registration No. 36,912

MAS:ct
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Brunner, Hans R.

Appl. No.: 10/612,338

Filed: July 3, 2003

For: **Compositions and Methods Involving
the Combination of a Thromboxane
A2 Receptor Antagonist and an Inhibitor
of Cyclooxygenase-2**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7571/80526

Second Supplemental Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, **MS Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Submitted herewith is a listing of documents known to Applicant and/or his attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents (with the exception of the United States patents) are also enclosed.

Applicant also wishes to make the Examiner aware of co-pending application 10/911,644, filed on August 5, 2004.

Applicant does not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicant does not believe any fee is due for the submission of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7571/80526.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By



Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicant

Date: March 31, 2005
1801 K Street, N.W., Suite 401L
Washington, DC 20006-1201
Phone: (202) 419-7013

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				Atty. Docket No.: 7571/80526		Appl No.: 10/612,338			
				Applicant(s) Brunner, Hans. R.					
				Filing Date: July 3, 2003				Group: to be assigned	

OFFICE
 APR 01 2005
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	AA 1	4,602,016	Jul. 22, 1986	Cross, <i>et al.</i>	514	234	Nov. 19, 1979	
	AB 1	4,636,500	Jan. 13, 1987	Cross, <i>et al.</i>	514	234	Mar. 21, 1985	
	AC							
	AD							
	AE							
	AF							
	AG							
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AH							
	AI							
	AJ							
	AK							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AL 1	BELHASSEN, <i>et al.</i> , "Improved Endothelial Function by the Thromboxane A ₂ Receptor Antagonist S 18886 in Patients with Coronary Artery Disease Treated with Aspirin," <i>J. Am. Coll. Cardiol.</i> 41:1198-1204 (2003).						
	AM1	CHENG, <i>et al.</i> , "Role of Prostacyclin in the Cardiovascular Response to Thromboxane A ₂ ," <i>Science</i> 296:539-541 (2002).						
	AN 1	HERING, <i>et al.</i> , "Sodium Valproate in the Prophylactic Treatment of Migraine: A Double-Blind Study Versus Placebo," <i>Cephalalgia</i> 12:81-84 (1992).						
	AO 1	MACONOCHE, <i>et al.</i> , "Evaluation of the Vascular Thromboxane A ₂ Receptor Blocking Activity of GR32191 in Man," <i>Proc. Brit. Pharmacol. Soc.</i> , July 6-8, 1988, p. 662P.						
	AP							
	AQ							
	AR							
	AS							
Examiner				Date Considered				